What is the recommended empiric therapy for uncomplicated vulvovaginal candidiasis in non‑pregnant women, and what alternatives are used for pregnant women or those unable to take oral azoles?

Empiric Treatment for Yeast Infection in Women

For uncomplicated vulvovaginal candidiasis in non-pregnant women, treat with either a single 150 mg oral dose of fluconazole OR any topical azole regimen (3-7 days), as both achieve equivalent cure rates >90%. 1, 2

First-Line Treatment Options

Oral Therapy (Preferred by Most Patients)

• Fluconazole 150 mg single oral dose - most convenient option 1, 2
• Equally effective as topical agents with high patient satisfaction

Topical Therapy (Over-the-Counter Options)

No single topical agent is superior to another 1, 2. Choose based on patient preference:

Short-course regimens (1-3 days):

• Miconazole 1200 mg vaginal suppository (single dose)
• Tioconazole 6.5% ointment 5g (single application)
• Clotrimazole 2% cream 5g daily × 3 days
• Miconazole 200 mg suppository daily × 3 days

Standard regimens (7 days):

• Clotrimazole 1% cream 5g daily × 7 days
• Miconazole 100 mg suppository daily × 7 days

Special Populations

Pregnant Women

Oral azoles are contraindicated in pregnancy. 1

Use topical azole therapy for 7 days minimum - longer courses may be needed:

• Clotrimazole 1% cream 5g daily × 7-14 days
• Miconazole 2% cream 5g daily × 7 days
• Terconazole 0.4% cream 5g daily × 7 days (prescription)

The 2022 CDC guidelines emphasize that topical azoles remain safe throughout all trimesters, with no demonstrated fetal harm despite theoretical concerns 1.

Severe Acute VVC

Fluconazole 150 mg every 72 hours × 2-3 doses (total of 300-450 mg over 4-6 days) 2

When Standard Therapy Fails

Non-albicans Species (C. glabrata)

If azole therapy fails and C. glabrata is confirmed:

1. Boric acid 600 mg intravaginal gelatin capsule daily × 14 days (requires compounding) 2
2. Alternative: Nystatin 100,000 units intravaginal suppository daily × 14 days 2
3. Third-line: Topical 17% flucytosine cream ± 3% amphotericin B cream daily × 14 days (requires compounding) 2

Recurrent VVC (≥4 episodes/year)

Two-phase approach: 2

1. Induction: Topical azole OR oral fluconazole × 10-14 days
2. Maintenance: Fluconazole 150 mg weekly × 6 months (achieves >90% symptom control)

Critical Diagnostic Considerations

Before empiric treatment, confirm diagnosis when possible 1, 2:

• Wet mount with 10% KOH - demonstrates yeast/hyphae (sensitivity ~58%, specificity ~89%)
• Vaginal pH 4.0-4.5 - higher pH suggests bacterial vaginosis or trichomoniasis
• PCR testing - superior sensitivity (91%) and specificity (94%) compared to microscopy 1

Common pitfall: Less than 50% of women self-diagnosing VVC actually have yeast infection 1. Clinical symptoms (pruritus, thick white discharge, dysuria) are nonspecific and overlap with other conditions.

Key Clinical Pearls

• HIV status does not alter treatment - identical regimens and response rates expected 2
• C. krusei responds to all topical azoles but is intrinsically fluconazole-resistant 2
• Azole resistance in C. albicans is extremely rare except after prolonged azole exposure 2
• After stopping maintenance therapy for recurrent VVC, expect 40-50% recurrence rate 2

Agents to Avoid for Empiric Therapy

• Nystatin - considered second-line due to inferior efficacy compared to azoles 3
• Boric acid - reserve for azole-refractory cases, not first-line 2
• Probiotics - insufficient evidence for routine use in acute treatment 4, 5